1
|
Xiao X, Ni Y, Yu C, Li L, Mao B, Yang Y, Zheng D, Silvestrini B, Cheng CY. Src family kinases (SFKs) and cell polarity in the testis. Semin Cell Dev Biol 2018; 81:46-53. [PMID: 29174914 PMCID: PMC5988912 DOI: 10.1016/j.semcdb.2017.11.024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Accepted: 11/20/2017] [Indexed: 01/02/2023]
Abstract
Non-receptor Src family kinases (SFKs), most notably c-Src and c-Yes, are recently shown to be expressed by Sertoli and/or germ cells in adult rat testes. Studies have shown that SFKs are involved in modulating the cell cytoskeletal function, and involved in endocytic vesicle-mediated protein endocytosis, transcytosis and/or recycling as well as intracellular protein degradation events. Furthermore, a knockdown to SFKs, in particular c-Yes, has shown to induce defects in spermatid polarity. These findings, coupled with emerging evidence in the field, thus prompt us to critically evaluate them to put forth a developing concept regarding the role of SFKs and cell polarity, which will become a basis to design experiments for future investigations.
Collapse
Affiliation(s)
- Xiang Xiao
- Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, China
- The Mary M. Wohlford Laboratory for Male Contraceptive Research, Center for Biomedical Research, Population Council, 1230 York Ave, New York, New York 10065
| | - Ya Ni
- Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, China
| | - Chenhuan Yu
- Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, China
| | - Linxi Li
- The Mary M. Wohlford Laboratory for Male Contraceptive Research, Center for Biomedical Research, Population Council, 1230 York Ave, New York, New York 10065
- The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzho, Zhejiang 325035, China
| | - Baiping Mao
- The Mary M. Wohlford Laboratory for Male Contraceptive Research, Center for Biomedical Research, Population Council, 1230 York Ave, New York, New York 10065
- The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzho, Zhejiang 325035, China
| | - Yue Yang
- Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, China
| | - Dongwang Zheng
- Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, China
| | | | - C. Yan Cheng
- The Mary M. Wohlford Laboratory for Male Contraceptive Research, Center for Biomedical Research, Population Council, 1230 York Ave, New York, New York 10065
| |
Collapse
|
2
|
Lundell G, Holm LE, Ljunggren JG, Wasserman J. Incidence of hypothyroidism after 131I therapy for hyperthyroidism. Relation to pretherapy serum levels of T3, T4 and thyroid antibodies. J Lipid Res 1982; 59:2255-2261. [PMID: 6277151 DOI: 10.1194/jlr.r084210] [Citation(s) in RCA: 80] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Revised: 04/05/2018] [Indexed: 12/13/2022] Open
Abstract
A correlation is reported between serum levels of triiodothyronine (S-T3) and thyroxine (S-T4) before treatment, as well as levels of thyroid antibodies before treatment, and the development of hypothyroidism following 131I therapy in 86 patients with hyperthyroidism. Patients with marked elevation of S-T3 or S-T4 had demonstrable antibodies to thyroid cytoplasmic antigen more often than those with normal or moderately elevated levels, and patients with markedly elevated levels of S-T3 also had a higher incidence of hypothyroidism after treatment. Patients with nodular thyroid glands and with markedly elevated levels of S-T3 required a larger number of 131I doses before no signs of hyperthyroidism persisted in comparison to those with moderately elevated levels.
Collapse
|